Year: 2024

TransUnion and Restaurant Dive report finds room for even greater profitability for nearly half of restaurants via loyalty programs CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Nearly two-thirds (64%) of Quick Service Restaurants (QSRs) reported increased traffic across all dayparts—times when they serve breakfast, lunch, and dinner— in 2024. Another 17% reported rising traffic in some dayparts, according to a new report from TransUnion (NYSE: TRU) and Restaurant Dive. Most QSR executives attribute this success to a focus on both communicating and capturing value with customers, an important step after 93% indicated they raised prices across the board in 2024. “Consumers may have become accustomed to inflation over the past couple years,” said Mark Rose, Senior Director of market strategy for TransUnion’s travel and hospitality business....

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024. Joshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day. To schedule a one-on-one meeting with Mr. Lev, investors are encouraged to reach out to their CG representative. For more information regarding the event please visit https://www.meetmax.com/sched/event_110807/conference_home.html. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation...

NAVIGATE trial on track for top-line results in December 2024NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S. with compensated cirrhosis, portal hypertension, and which have not developed esophageal varices. These patients represent a large unmet medical...

Tokyo, Nov. 14, 2024 (GLOBE NEWSWIRE) — Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America and the United Kingdom, today announced the launch of a new online sales platform for its Reiwatakiya brand in Canada. The platform, available at https://reiwatakiyatoronto.com, will serve as a one-stop online hub for North American customers, offering authentic Japanese health, beauty, and lifestyle products with local shipping options across North America. This launch represents a major milestone in the Company’s regional expansion strategy. Mr. Mei Kanayama, Principal Executive Officer of Tokyo Lifestyle, commented, “The North American...

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days. About Korro Korro is a...

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.Stifel 2024 Healthcare ConferenceDate: Monday, November 18, 2024Time: 4:10PM ETFormat: Fireside ChatLocation: Lotte New York Palace, New YorkWebcast Link  A link for this live webcast will also be accessible through the “events & presentations” page in the investors section of X4 Pharmaceuticals’ website. After the conclusion of the conference, a webcast replay will be available through the same link. The Company will be available for one-on-one meetings during this conference. Interested investors...

MONTRÉAL, Nov. 14, 2024 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian health tech company, announces that it successfully deployed AI at its two subsidiaries to meet its digital transformation, efficiency and sustainability objectives. Premier Health has deployed AI capabilities at its two Quebec per diem subsidiaries, Premier Soin and Code Bleu. The AI’s maturity has achieved a remarkable 89% precision rate in interpreting client data, which minimizes manual intervention and allows team members to focus on client support and resource allocation. Overall operational efficiency has increased by 25%, with a 20% reduction in time spent on recurring tasks since the rollout.  The Corporation expects further material improvement as AI is deployed at other subsidiaries...

Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Operations to Achieve Next Interim Read-Out and Fund Current RenovoCath Commercialization Efforts LOS ALTOS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, today announced its financial results and operational highlights for the third quarter ended...

PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST. The presentation will be accessible via a live webcast. The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net. Learn more about Integer at www.integer.net. About Integer®Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world,...